Drug Trial News

RSS

Combination of two targeted drugs shows "clinically meaningful" activity in some malignant brain tumors

A combination of two targeted cancer drugs showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.

25 Nov 2021

Oral Hsp90 inhibitor SNX-5422 interferes with replication machinery of SARS-CoV-2

A new study evaluates the efficacy of SNX-5422 as a post-exposure prophylactic treatment.

23 Nov 2021

Tobacco mosaic virus nanoparticle-based novel COVID-19 vaccine candidate

Scientists generate a VLP type NP platform made of recombinant viral antigens conjugated with TMV virions.

23 Nov 2021

Inactivated virion-based vaccine confers robust cell-mediated immunity against major SARS-CoV-2 variants

Indian researchers determine the magnitude, quality, and persistence of cellular and humoral memory responses after vaccination with BBV152/Covaxin.

23 Nov 2021

CoronaVac vaccine booster strengthens protection against SARS-CoV-2

In a recent study published on the preprint medRxiv* server, an international team of scientists tested CoronaVac as a booster shot and measured its effects on immunity. Their findings showed increases in neutralizing antibodies and T cell response.

21 Nov 2021

A nasal COVID vaccine using a weakened influenza vector

The authors of a new study, published on the bioRxiv* preprint server, constructed a COVID-19 nasal vaccine candidate by inserting a gene encoding the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2, named CA4-dNS1-nCoV-RBD (dNS1-RBD) in a live attenuated influenza virus (LAIV) vector.

18 Nov 2021

REGEN-COV is effective in preventing severe COVID-19 in immunocompromised individuals

A recent study assesses the efficacy of repeat doses of REGEN-COV in SARS-CoV-2-negative adults who were healthy or had chronic medical conditions.

18 Nov 2021

Researchers receive $22 million grant for clinical trial that aims to reduce lung transplant rejection

Physicians at Washington University School of Medicine in St. Louis and Massachusetts General Hospital/Harvard Medical School in Boston have received a seven-year, $22 million grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to help lead a multicenter clinical trial evaluating whether a novel immunosuppressant can reduce the risk of organ rejection after a lung transplant.

18 Nov 2021

Study shows neutralizing capacity of monoclonal antibodies against SARS-CoV-2 variants of concern

Canadian public health researchers recently published a study in the journal Antiviral Research wherein they described generating a panel of murine hybridomas recognizing SARS-CoV-2 spike protein or nucleoprotein, capable of neutralizing the SARS-CoV-2 variants of concern, proving their therapeutic potential.

17 Nov 2021

Inhaled prostacyclin improves oxygenation in acute respiratory distress syndrome patients

The findings reveal that inhaled prostacyclin significantly improves oxygenation in ARDS patients who had COVID-19. The study is currently available on the medRxiv* preprint server.

17 Nov 2021

Drug improved cardiac structure and function in patients with early-stage hypertrophic cardiomyopathy

Valsartan, an angiotensin II receptor blocker drug, delayed disease progression and improved cardiac structure and function in patients with early-stage hypertrophic cardiomyopathy, according to results from a recent clinical trial published in Nature Medicine.

16 Nov 2021

A therapeutic interfering particle for SARS-CoV-2

Researchers report their attempt to engineer TIPs that can conditionally replicate with SARS-CoV-2, inhibit viral replication 10–100 fold, and exhibit R0>1.

16 Nov 2021

Immune response elicited by SARS-CoV-2 vaccines in infliximab and vedolizumab-treated patients with IBD

A recent study evaluates the immune responses elicited by COVID-19 vaccines in infliximab- or vedolizumab-treated IBD patients.

15 Nov 2021

Promising results from Phase II REGEN-COV study

Initial results of the REGEN-COV Phase II study are presented.

15 Nov 2021

Oral PCSK9-inhibitor highly effective at reducing high levels of LDL cholesterol, studies show

Results from two early clinical studies show the first version of an oral PCSK9-inhibitor cholesterol-lowering medicine was well tolerated and highly effective at reducing high levels of LDL cholesterol, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2021.

15 Nov 2021

Prescription omega-3 pill did not reduce hospitalization or death from COVID-19

A high dose of a purified omega-3 fatty acid, available by prescription only, was well tolerated; however, it did not substantially reduce incidents of hospitalizations and/or deaths among people with COVID-19, according to a late-breaking clinical trial presented today at the American Heart Association's Scientific Sessions 2021.

15 Nov 2021

Analysis of immunodeficient patients granted REGEN-COV under compassionate use COVID-19 program

A team of scientists describe the safety and response to REGEN-COV® for COVID-19 patients with immunodeficiency-associated antibody disorders.

11 Nov 2021

Study shows 90.7% efficacy for the BNT162b2 COVID vaccine in 5-11 year-olds

A new study evaluates the safety, immunogenicity, and efficacy of the BNT162b2 in children who were 5 to 11 years of age.

11 Nov 2021

University of Oxford begins Phase I trial to test Ebola vaccine

The University of Oxford have begun recruiting for a Phase I trial to test an Ebola vaccine in human volunteers - with the first vaccinations taking place today (Thursday, 11 November).

11 Nov 2021

Effectiveness of sotrovimab demonstrated in patients with mild to moderate COVID-19

In an attempt to study the safety and effectiveness of sotrovimab in more vulnerable patients suffering from mild to moderate symptoms of COVID-19, a multinational team of researchers conducted the COVID-19 Monoclonal antibody Efficacy Trial-Intent to Care Early (COMET-ICE) trial.

11 Nov 2021

Previous
1
...
60
61
62
63
64
65
66
...
1162
Next

Drug Trial News

Combination of two targeted drugs shows "clinically meaningful" activity in some malignant brain tumors

Oral Hsp90 inhibitor SNX-5422 interferes with replication machinery of SARS-CoV-2

Tobacco mosaic virus nanoparticle-based novel COVID-19 vaccine candidate

Inactivated virion-based vaccine confers robust cell-mediated immunity against major SARS-CoV-2 variants

CoronaVac vaccine booster strengthens protection against SARS-CoV-2

A nasal COVID vaccine using a weakened influenza vector

REGEN-COV is effective in preventing severe COVID-19 in immunocompromised individuals

Researchers receive $22 million grant for clinical trial that aims to reduce lung transplant rejection

Study shows neutralizing capacity of monoclonal antibodies against SARS-CoV-2 variants of concern

Inhaled prostacyclin improves oxygenation in acute respiratory distress syndrome patients

Drug improved cardiac structure and function in patients with early-stage hypertrophic cardiomyopathy

A therapeutic interfering particle for SARS-CoV-2

Immune response elicited by SARS-CoV-2 vaccines in infliximab and vedolizumab-treated patients with IBD

Promising results from Phase II REGEN-COV study

Oral PCSK9-inhibitor highly effective at reducing high levels of LDL cholesterol, studies show

Prescription omega-3 pill did not reduce hospitalization or death from COVID-19

Analysis of immunodeficient patients granted REGEN-COV under compassionate use COVID-19 program

Study shows 90.7% efficacy for the BNT162b2 COVID vaccine in 5-11 year-olds

University of Oxford begins Phase I trial to test Ebola vaccine

Effectiveness of sotrovimab demonstrated in patients with mild to moderate COVID-19

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News